Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Market price (% of par)
-
140.39%
-
Total 13F principal
-
$96,569,000
-
Principal change
-
-$114,875,000
-
Total reported market value
-
$135,608,000
-
Number of holders
-
20
-
Value change
-
-$99,945,335
-
Number of buys
-
6
-
Number of sells
-
17
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q1 2021
As of 31 Mar 2021,
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 was held by
20 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$96,569,000
in principal (par value) of the bond.
The largest 10 bondholders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), MACKAY SHIELDS LLC, JPMORGAN CHASE & CO, AMERIPRISE FINANCIAL INC, WELLS FARGO & COMPANY/MN, LMR Partners LLP, Opti Capital Management, LP, CAPSTONE INVESTMENT ADVISORS, LLC, Farallon Capital Management, L.L.C., and WOLVERINE ASSET MANAGEMENT LLC.
This page lists
21
institutional bondholders reporting positions
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.